Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience.
Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, Kugathasan S, Pfefferkorn M, Tolia V, Evans J, Treem W, Wyllie R, Rothbaum R, del Rosario J, Katz A, Mezoff A, Oliva-Hemker M, Lerer T, Griffiths A; Pediatric Inflammatory Bowel Disease Collaborative Research Group. Hyams J, et al. J Pediatr Gastroenterol Nutr. 2005 Oct;41(4):416-21. doi: 10.1097/01.mpg.0000183350.46795.42. J Pediatr Gastroenterol Nutr. 2005. PMID: 16205508
Natalizumab therapy for moderate to severe Crohn disease in adolescents.
Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, Daniels R, Libonati MA, Zanker S, Kugathasan S; International Natalizumab CD305 Trial Group. Hyams JS, et al. J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):185-91. doi: 10.1097/01.mpg.0000252191.05170.e7. J Pediatr Gastroenterol Nutr. 2007. PMID: 17255829 Clinical Trial.
Intercenter variation in initial management of children with Crohn's disease.
Kappelman MD, Bousvaros A, Hyams J, Markowitz J, Pfefferkorn M, Kugathasan S, Rosh J, Otley A, Mack D, Griffiths A, Evans J, Grand R, Langton C, Kleinman K, Finkelstein JA. Kappelman MD, et al. Among authors: hyams j. Inflamm Bowel Dis. 2007 Jul;13(7):890-5. doi: 10.1002/ibd.20121. Inflamm Bowel Dis. 2007. PMID: 17286275
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group. Hyams J, et al. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. Epub 2006 Dec 3. Gastroenterology. 2007. PMID: 17324398 Clinical Trial.
Course and treatment of perianal disease in children newly diagnosed with Crohn's disease.
Keljo DJ, Markowitz J, Langton C, Lerer T, Bousvaros A, Carvalho R, Crandall W, Evans J, Griffiths A, Kay M, Kugathasan S, LeLeiko N, Mack D, Mamula P, Moyer MS, Oliva-Hemker M, Otley A, Pfefferkorn M, Rosh J, Hyams JS. Keljo DJ, et al. Among authors: hyams js. Inflamm Bowel Dis. 2009 Mar;15(3):383-7. doi: 10.1002/ibd.20767. Inflamm Bowel Dis. 2009. PMID: 19023863
Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study.
Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN; Reach Study Group. Thayu M, et al. Among authors: hyams js. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1378-84. doi: 10.1016/j.cgh.2008.07.010. Clin Gastroenterol Hepatol. 2008. PMID: 19081527 Clinical Trial.
Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology?
Markowitz J, Kugathasan S, Dubinsky M, Mei L, Crandall W, LeLeiko N, Oliva-Hemker M, Rosh J, Evans J, Mack D, Otley A, Pfefferkorn M, Bahar R, Vasiliauskas E, Wahbeh G, Silber G, Quiros JA, Wrobel I, Nebel J, Landers C, Picornell Y, Targan S, Lerer T, Hyams J. Markowitz J, et al. Among authors: hyams j. Inflamm Bowel Dis. 2009 May;15(5):714-9. doi: 10.1002/ibd.20831. Inflamm Bowel Dis. 2009. PMID: 19107777 Free PMC article.
Long-term outcome of maintenance infliximab therapy in children with Crohn's disease.
Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A, Rosh J, Mamula P, Kay M, Crandall W, Oliva-Hemker M, Keljo D, LeLeiko N, Markowitz J; Pediatric Inflammatory Bowel Disease Collaborative Research Group. Hyams JS, et al. Inflamm Bowel Dis. 2009 Jun;15(6):816-22. doi: 10.1002/ibd.20845. Inflamm Bowel Dis. 2009. PMID: 19107783
Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH.
Crandall W, Hyams J, Kugathasan S, Griffiths A, Zrubek J, Olson A, Liu G, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano RN. Crandall W, et al. Among authors: hyams j. J Pediatr Gastroenterol Nutr. 2009 Aug;49(2):183-90. doi: 10.1097/MPG.0b013e3181a70f21. J Pediatr Gastroenterol Nutr. 2009. PMID: 19561542 Clinical Trial.
467 results